PROGNOSTIC VALUE OF MATRIX METALLOPROTEINASE 9 IN RENAL CELL CARCINOMA
T. M. Cherdantseva,
I. P. Bobrov,
S. V. Varlamov,
M. N. Myadelets,
I. V. Klimachev,
A. M. Avdalyan,
D. I. Ganov,
A. F. Lazarev https://doi.org/10.17650/1726-9776-2018-14-3-17-24
Abstract
Objective: to assess matrix metalloproteinase 9 (MMP-9) expression in renal cell carcinoma cells and cells of intratumoral inflammatory infiltrates depending on clinical and morphological characteristics and postoperative survival.
Materials and methods. We evaluated MMP-expression in 108 renal cancer tissue specimens. The intensity of immunohistochemical staining was estimated by measuring integral optical density in cytoplasm.
Results. We found that the integral optical density of MMP-9 immunostaining in tumor cells and cells of intratumoral inflammatory infiltrates correlates with important prognostic factors for renal cancer, including histological type of cancer, TNM stage, tumor size, Fuhrman nuclear grade, metastasis, and 5-year postoperative survival.
Conclusion. Integral optical density of MMP-9 immunostaining is an additional prognostic factor for renal cell carcinoma.
About the Authors
T. M. Cherdantseva
Altai State Medical University, Ministry of Health of Russia; Altai Branch of the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
I. P. Bobrov
Altai State Medical University, Ministry of Health of Russia; Altai Branch of the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
S. V. Varlamov
Altai Branch of the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
Russian Federation
77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
M. N. Myadelets
Altai State Medical University, Ministry of Health of Russia
Russian Federation
40 Lenina St., Barnaul 656038.
Competing Interests: No conflict of interest.
Russian Federation
40 Lenina St., Barnaul 656038.
Competing Interests: No conflict of interest.
I. V. Klimachev
Altai State Medical University, Ministry of Health of Russia
Russian Federation
40 Lenina St., Barnaul 656038.
Competing Interests: No conflict of interest.
Russian Federation
40 Lenina St., Barnaul 656038.
Competing Interests: No conflict of interest.
A. M. Avdalyan
Altai Branch of the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
Russian Federation
77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
D. I. Ganov
Altai State Medical University, Ministry of Health of Russia; Altai Branch of the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
A. F. Lazarev
Altai State Medical University, Ministry of Health of Russia; Altai Branch of the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
Russian Federation
40 Lenina St., Barnaul 656038; 77 Nikitina St., Barnaul 656049.
Competing Interests: No conflict of interest.
References
1. Spirina L.V., Kondakova I.N., Klisho E.V. et al. Metaloproteinases as neoangiogenesis regulators in cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2007;(1):67–71. (In Russ.).
2. Dufour A., Sampson N.S., Zucke S., Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. Cell Physiology 2008;217(3):643–51. DOI: 10.1002/jcp.21535. PMID: 18636552.
3. Vihinen P., Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99(2):157–66. DOI: 10.1002/ijc.10329. PMID: 11979428
4. Ganusevich I.I. Role matrix metalloproteinases (MMP) in malignancies. II Participation of MMPs in angiogenesis, invasion and metastasis of tumors. Onkologiya = Oncology 2010;(2):108–17. (In Russ.).
5. Mook O.R., Frederiks W.M., Van Noorden C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004;1705(2):69–89. DOI: 10.1016/j.bbcan.2004.09.006. PMID: 15588763.
6. Shaco-Levy R., Sharabi S., Benharroch D. et al. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. Eur J Obstet Gynecol Reprod Biol 2008;139(2):226–32. DOI: 10.1016/j.ejogrb.2008.01.004. PMID: 18295959.
7. Di Carlo A. Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma. Oncol Rep 2012;28(3): 1051–6. DOI: 10.3892/or.2012.1864. PMID: 22711190.
8. Lin H., Pan J.C., Zhang F.M. et al. Matrix metalloproteinase-9 is required for vasculogenic mimicry by clear cell renal carcinoma cells. Urol Oncol 2015;33(4):9–16. DOI: 10.1016/j.urolonc.2014.12.007. PMID: 25618297.
9. Qiao Z.K., Li Y.L., Lu H.T. et al. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. World J Surg Oncol 2013;11:1–6. DOI: 10.1186/1477-7819-11-1. PMID: 23281640.
10. Shchukin D.V., Lesovoy V.N., Yakovtsova I.I. et al. Activity of matrix metalloproteinase 9 (MMP-9) with intravenous extension of advanced renal cell carcinoma. Vestnik problem biologii i meditsiny = Bulletin of Problems of Biology and Medicine 2015;(2):283–9. (In Russ.).
11. Cho N.H., Shim H.S., Rha S.Y. et al. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 2003;44(5):560–6. PMID: 14572755.
12. Kawata N., Nagane Y., Hirakata H. et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 2007;69(6):1049–53. DOI: 10.1016/j.urology.2007.02.044. PMID: 17572184.
Review
For citations:
Cherdantseva T.M., Bobrov I.P., Varlamov S.V., Myadelets M.N., Klimachev I.V., Avdalyan A.M., Ganov D.I., Lazarev A.F. PROGNOSTIC VALUE OF MATRIX METALLOPROTEINASE 9 IN RENAL CELL CARCINOMA. Cancer Urology. 2018;14(3):17-24. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-3-17-24
Views:
889
Email this article 